Download
10.1186_s40463-020-00446-1.pdf 535,77KB
WeightNameValue
1000 Titel
  • Clinicopathologic implications of Myb and Beta-catenin expression in adenoid cystic carcinoma
1000 Autor/in
  1. Park, Susan |
  2. Vora, Manali |
  3. van Zante, Annemieke |
  4. Humtsoe, Joseph |
  5. Kim, Hyun-Su |
  6. Yom, Sue |
  7. Agarwal, Shweta |
  8. Ha, Patrick |
1000 Verlag
  • SAGE Publications
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-01-01
1000 Erschienen in
1000 Quellenangabe
  • 49(1)
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s40463-020-00446-1 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350736/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:sec><jats:title>Background</jats:title><jats:p> Adenoid cystic carcinoma (ACC) is the second most common malignancy of the salivary glands, accounting for ∼ 1% of malignant tumors of the head and neck region and 10% of salivary gland neoplasms. Predicting the long-term outcomes of patients with ACC is still challenging, as reliable prognostic biomarkers are not available. Among salivary gland tumors, Myb overexpression is highly specific for ACC. In addition, the MYB-NF1B fusion translocation is a hallmark of ACC, and although the detection of this translocation does not appear to impact prognosis, the MYB-NF1B fusion is also implicated in MYB upregulation. Myb has recently been identified as an activator of the Wnt/β-catenin signaling pathway, and aberrant cytoplasmic expression of β-catenin has been observed in many salivary gland malignancies. In this study, we aim to analyze the impact of Myb and β-catenin expression on prognosis in ACC. </jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p> A tissue microarray constructed from archival tissue from 64 patients with ACC was stained for Myb and β-catenin; both localization and intensity were evaluated. In parallel, we abstracted demographic data, tumor characteristics, survival data, and outcomes, including local recurrence, regional recurrence, and distant metastasis from the medical record. Statistical analysis was performed. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Our analysis supports that ACC patients negative for Myb by immunohistochemical methods have a higher risk of developing metastasis than patients with Myb staining (HR: 4.06, 95% CI: 1.02–14.96, p-value: 0.03). Although not statistically significant, cytoplasmic localization of β-catenin is may suggest a diminished rate of relapse-free survival (HR 2.45, 95%CI: 0.9–6.7, p = 0.08). Furthermore, Myb expression correlated with β-catenin expression, increasing 1.69 in staining intensity units with each increase in β-catenin staining intensity ( p-value: 0.04). </jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p> Our study suggests that Myb expression is protective; Myb positive patients have diminished risk of distant metastasis. In contrast, there is a trend towards increased hazard of death in ACC patients with cytoplasmic β-catenin expression. Additional analyses will be necessary to establish Myb and β-catenin as independent protective and adverse biomarkers, respectively. </jats:p></jats:sec>
1000 Sacherschließung
lokal Prognostic indicator
lokal Proto-Oncogene Proteins c-myb/metabolism [MeSH]
lokal Beta-catenin
lokal Tissue Array Analysis [MeSH]
lokal beta Catenin/genetics [MeSH]
lokal Age of Onset [MeSH]
lokal Male [MeSH]
lokal Carcinoma, Adenoid Cystic/metabolism [MeSH]
lokal Original Research Article
lokal Neoplasm Recurrence, Local [MeSH]
lokal Adenoid cystic carcinoma
lokal Female [MeSH]
lokal beta Catenin/metabolism [MeSH]
lokal Translocation, Genetic [MeSH]
lokal Humans [MeSH]
lokal Neoplasm Metastasis [MeSH]
lokal Salivary Gland Neoplasms/metabolism [MeSH]
lokal Middle Aged [MeSH]
lokal Carcinoma, Adenoid Cystic/mortality [MeSH]
lokal Biomarkers, Tumor/metabolism [MeSH]
lokal Salivary Gland Neoplasms/mortality [MeSH]
lokal Proto-Oncogene Proteins c-myb/genetics [MeSH]
lokal Biomarkers, Tumor/genetics [MeSH]
lokal Prognosis [MeSH]
lokal Myb
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/UGFyaywgU3VzYW4=|https://frl.publisso.de/adhoc/uri/Vm9yYSwgTWFuYWxp|https://frl.publisso.de/adhoc/uri/dmFuIFphbnRlLCBBbm5lbWlla2U=|https://frl.publisso.de/adhoc/uri/SHVtdHNvZSwgSm9zZXBo|https://frl.publisso.de/adhoc/uri/S2ltLCBIeXVuLVN1|https://frl.publisso.de/adhoc/uri/WW9tLCBTdWU=|https://frl.publisso.de/adhoc/uri/QWdhcndhbCwgU2h3ZXRh|https://orcid.org/0000-0003-0306-6147
1000 Hinweis
  • DeepGreen-ID: b03ba5c6620b41799f419847a7b03ce0 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. National Institutes of Health |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer National Institutes of Health |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6478000.rdf
1000 Erstellt am 2024-05-21T12:22:25.773+0200
1000 Erstellt von 322
1000 beschreibt frl:6478000
1000 Zuletzt bearbeitet Wed May 22 09:39:46 CEST 2024
1000 Objekt bearb. Wed May 22 09:39:46 CEST 2024
1000 Vgl. frl:6478000
1000 Oai Id
  1. oai:frl.publisso.de:frl:6478000 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source